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Donovan (1), in a masterful discourse on concepts of disease mechanisms,
states, in part, that in the rational study of a disease process we endeavor first
to identify the clinical hallmarks of that process. Pathological or biochemical
aberrations are then correlated with the clinical findings. With this information
at hand, an attempt is then made to seek out the causative factors. Then the
"how" and the "why" of disease evolution is related to the total frame of the
morbid process. While the clinical and histopathological features of diffuse
scleroderma and acroscierosis have been adequately documented (2—15, 19),
much remains to be learned as to even the gross features of the pathophysiology
and biochemistry of this sclerotic anomaly.
Re-evaluation of the existing clinical, histopathologic and experimental
knowledge of the collagenous diseases, especially as applies to generalized sclero-
derma and acrosclerosis, would justify a reassessment of the scierosing connec-
tive tissue diseases. Several challenging concepts, together with experimental
work at the laboratory level, appear to give new insights into the intricacies of
this variety of collagenous disease.
Schroeder (16), in an intriguing approach wherein he correlates trace metals
and chronic diseases, emphasizes the possibility that some of the chronic and
morbid afflictions of civilized man may represent essentially an aberration in
trace or abnormal metal actions: trace metal deficiency, abnormal metal excess,
metallo-enzyme competition by an extraneous metal, and the dependence of
many metallo-enzyme systems upon chelation. Significantly, this investigator
cites several categories of disease wherein the above little understood abnormali-
ties may play a role: the collagenous diseases, atherosclerosis, some drug reac-
tions, some neurological disorders (Wilson's disease), and vitamin B complex
deficiencies. it is of interest in this regard to ponder the thought, never proven,
that scleroderma might in some unexplained manner be related to an elusive and
possibly even subtle derangement of calcium metabolism (17, 18). That the role
of dynamic disease processes and trace and abnormal metal relationships is not
a random observation is further emphasized by this investigator (16) when he
enumerates those circumstances wherein therapeutic effects are achieved in part
at least by chelating and metal-binding properties of drugs: BAL, antithyroid
drugs, antibiotics, analgesics, antipyretics, etc. The application of the latter
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knowledge to the many treatment programs of scieroderma strikes one forcibly in
that some of the drugs that have been exhibited appear to act, in part, on metal-
binding interrelationships: PABA (20), citric acid (21), dihydrotachysterol (22),
promin (23), ACTII and cortisone (24-28), penicfflin (29), cinchoninic acid
(30), and prednisone (31).
Recent investigations appear to lend credence to the view that the metabolism
of calcium represents a large integrated physico-chemical system embracing not
only extra-cellular fluids and bone but connective tissue as well. Tui et at. (32),
as a result of their studies in protein metabolism and scleroderma, suggest that
an insidiously developing protein depletion might lead to a substitution of colla-
gen and calcium for its normal protein components. Meyer and Rapport (33) in
their studies have noted that the sulfated mucopolysaccharides, of which chon-
droitin sulfate is the best known, are found essentially in the supporting tissues
of the body, serving as the chief component of cartilage, tendon, heart
valves, skin and walls of large blood vessels. They concluded that the ubiquitous
sulfated mucopolysaccharides of the ground substance seemed to serve as cation
exchange resins in a complex physiological system. Boyd and Neuman (34)
measured the binding of electrolytes by ground cartilage packed in glass columns
and were able to demonstrate that the binding represented an ion exchange
reaction due primarily to the chondroitin sulfate present. The binding capacities
of sodium, calcium, and barium were noted to be equal. That the chondroitin
sulfate of the skin in animals differed from that of the aorta, synovial fluid, and
cartilage was later demonstrated by Meyer (35) in in vitro experiments. Neuman
et at (36), utilizing columns containing pulverized demineralized cartilage through
which was passed various solutions of cations, found that 1 mgm. of cation (cal-
cium, sodium, barium) was bound to 1 gm. of dry cartilage (sulfate content 1
meq./gm.). They found an excellent correlation between cation binding capacity
and sulfate content. They concluded, in part, that chondroitin sulfate in cartilage
combined with cations, not with anions, by a process of ion exchange. Engel et at
(37) studied the electrochemical potential across various connective tissues and
noted that the calcium content of these tissues was related to the density of the
negatively charged colloid tissue (the latter being defined as consisting of all im-
mobile charged macromolecules of the tissue). They were able to demonstrate
that dense connective tissue (cartilage) contained ionic and bound calcium far
exceeding that of blood. The skin of rabbits and monkeys was noted to likewise
exceed that of blood, especially the bound form. In all the tissues studied by
them, a relatively constant fraction of connective tissue was bound by calcium.
Engel et at (38) in a subsequent report, underscored the concept that the extra-
cellular fluid and ground substance are part and parcel of one physico-chemical
system. Armstrong (39) in a discussion of their paper raised the possibility that
the connective tissue which does not calcify might accumulate calcium. Calkins
et at (40) in a comprehensive review of the metabolism and clinical significance
of the carbohydrate compounds of connective tissue presented the recent ad-
vances in this broad area, particularly emphasizing the many still unknown facets
of the dynamic connective tissue processes. Rubin (41, 42) demonstrated that
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chelating agents (EDTA) seemed to serve as an aid in the delineation of calcium
metabolism and furthermore outlined their application in clinical medicine. This
worker likewise noted that when this agent is introduced into a physiological
environment its primary gross action is on the divalent cation present in greatest
concentration, namely calcium.
This study reports our experiences in the treatment of three cases of non-cal-
cific scieroderma (acroscierosis) by means of disodium ethylenediamine tetra-
acetic acid (hereinafter referred to as Na2-EDTA) *•The experiences of Klein and
Harris (43), who successfully treated with this drug a female suffering from a
severe form of calcific scieroderma, together with the newer concepts and experi-
mental data outlined above, gave rise to the possibility that treatment with this
chelating agent would represent a rational assault on this chronic and morbid
process. The biochemical changes found to be present in these patients and their
modification or correction by Na2-EDTA (Endrate), pyridoxine. and nicotina-
mide will form the subject of another report (44\,
Case I, female, 31 years of age, hospital number 309815, was admitted to the University
Hospitals for the second time November18, 1956, for treatment of "scieroderma". According
to the patient, her present difficulties appeared to extend over a 4 year period: pain, swelling
and stiffness of the hands worse in winter; recurrent "ulcers" of the fingertips and elbow;
recent "gangrene" of the middle finger of the right hand; "arthritis" of the wrists, elbows,
shoulders, back, hips and knees; "tightness" and "hardness" of the skin of the face, neck,
and especially the upper extremities. The onset of the disease in the fall of 1953 embraced
essentially the hands and consisted of swelling, immobility, pain and pallor when exposed to
cold weather. When seen by her physician at that time the possibility of a circulatory im-
balance was considered most likely. She was told to stop smoking and was placed on pris-
coline and cortisone with no remarkable change in the clinical picture. While on this regimen
small painful ulcers appeared on the fingers of the hands. In the spring of 1955 the patient
became pregnant and noted for the first time a diminution of pain and a healing of the ulcers
of the hands. Approximately 2 months after the termination of a normal pregnancy her
condition was noted to worsen with recurrence of hand symptoms together with the onset of
facial and upper extremity skin tightness and a generalized "arthritis". She was no longer
able to wrinkle her brow, smile, or open her mouth fully (dental observation). At this time
she was seen by several physicians and placed next on PABA therapy and eventually Di-
benzyline. No remarkable changes were noted as a result of these therapeutic approaches.
Because of further clinical deterioration (pain, inability to do housework, etc.), she was
admitted to this hospital. Additional history was non-contributory.
Pertinent physical findings were those of the cutaneous system. The skin of the face,
neck, upper chest, and the extremities was indurated, shiny and bound-down. Increased
pigmentation was noted in the neck and upper extremities. The tip of the right finger
presented a small painful ulceration, together with redness, swelling, tenderness of the
distal phalanx, and an accompanying nail deformity. The fingers of the hands were thin,
elongated, and fixed in a position of fiexion. Movement of the shoulders, elbows, wrists,
fingers, back, hips, and knees was accompanied by pain. There was erythema, warmth, and
exquisite tenderness over the wrist area. The right elbow was fixed in a moderate fiexion
position. Excepting for a blood pressure of 90/70, other physical findings were
non-contributory
Laboratory Data: Hemoglobin 13.9 gm. and a white blood count of 8,300 with a normal
differential. The serologic findings were negative. The urinary examination was negative
*Endrate was kindly furnished by Rodney Gwinn, M.D., Abbott Research Laboratories,
North Chicago, Illinois.
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for glucose, albumin and casts. Fasting blood sugar 94 mg. %. Nonprotein nitrogen was
found to be 22mg. %.The bleeding time, coagulation time and platelets were normal. Total
serum protein was 7.9 gm. with an albumin of 4.7 gm. and globulin of 3.2 gm. Hanger's test
was 1+. Thymol turbidity was reported as 9.0 units. Total serum bilirubin 0.8 mg. with a
direct fraction of 0.05 mg. Prothrombin time was normal (100%). Blood uric acid was found
to be 3.8 mg. % and C-reactive protein was 1+. Serum sodium, chlorides and potassium were
140, 109 and 4.0 meq./L. respectively. Serum calcium was 9.4 mg. % and that of phosphorus
3.2 mg %. 24 hour urinary excretion of copper and zinc was .13 mg./L. and 0.57 mg./L
respectively. Smears for L.E. cells were negative. Free boundary electrophoresis was found
to be normal. Biopsy study of the skin of the dorsum of the hand was consistent with that of
seleroderma. Von Kossa stain for calcium was negative. The ECG, chest and gastroin-
testinal x-rays were normal. There was no roentgenographic evidence of calcification of the
upper extremities. The changes in the terminal phalanges of the fingers were consistent with
scleroderma.
Therapy consisted of 3 gm. of Na2-EDTA (Endrate) given intravenously daily over a 4
hour period for five days. Three consecutive weekly courses (45 gm.) constituted the treat-
ment program. Significant changes were noted to appear during the second week of therapy.
Most striking changes appeared to involve the cutaneous and osseous systems. The previous
inability to wrinkle the forehead, smile and open the mouth were favorably profoundly
altered. The skin of the face, neck, and upper extremities appeared to be less tense and
indurated. The skin over the hands, while less bound-down, appeared to be least affected by
therapy. While clinical range of motion maneuvers were not remarkably changed, the ab-
sence of pain on motion was striking. The exquisite tenderness of the wrists was unchanged.
The fingers of the hands appeared to be warmer. Temperature challenge (cold) of the digits
eventuated only in slight pain. Biopsy study of the skin (dorsum, hand) showed an increased
prominence of rete ridges, less dense fibrous tissue in the corium, adnexal structure in-
creased, and an increase in subcutaneous fatty tissue. At no time during the course of
therapy or after was there found any adverse change in the complete laboratory evaluation
of the patient. Even though the serum calcium levels, determined shortly after the infusion,
decreased to 5.8 mg. %, no clinical evidence of tetany was encountered. Generally, with the
exception of pain near the intravenous site, the patient tolerated the procedure well.
Interestingly, 24 hour urinary copper and zinc excretion showed a progressive increase,
especially in the zinc fraction (9.97 mg./L.). No evidence of clinical avitaminosis B as
described by others (63, 65) occurred during or after intravenous therapy. The patient was
discharged from the hospital as improved, November 21, 1956. She was instructed to take
the Na2-EDTA orally, 1.5 gIn, daily. The clinical change that had taken place in the patient
was noted by the family, her friends and her dentist. She was followed on an outpatient basis
and the general improvement noted on discharge appeared to be maintained; however, the
exquisite wrist tenderness and pain remained unchanged.
The patient was readmitted for the third time January 6, 1957, for evaluation of her
clinical status and further biochemical study. Complete laboratory evaluation revealed no
remarkable or significant alterations. The patient was placed upon her second course of
intravenous therapy (3 weeks, 45 gm.). Clinical re-assessment appeared to indicate a
progressive, though moderate, decrease in skin induration. The residual joint pain seemed
to diminish further. The wrist pain remained totally resistant to the drug. Calibrated range
of motion studies, skin temperature, oscillometric determinations and histamine wheal
procedures were essentially unaltered in before and after determinations. The patient was
discharged from the hospital February 9, 1957, as further improved. She was placed on high
pharmacological doses of pyridoxine and nicotinamide on the basis of unusual biochemical
changes discovered during the course of investigation.
Case II, female, 52 years, hospital number 311414, was admitted to the University Hos-
pitals October17, 1956, because of "hardness" of skin of the face and hands, "arthritis", and
nausea and vomiting of 2 years duration. According to the patient, her present difficulty
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began with "pain" and swelling of the hands, wrists, and knees. Prior to the onset of the
above symptoms she had noted an excessive sweating of the hands and feet with "whiteness"
and "blueness" appearing in these digits after exposure to cold. Her family physician recom-
mended aspirin for her "arthritis"; but there was no apparent relief. In May, 1956, nausea
and vomiting appeared, apparently related to greasy or highly spiced foods and certain
vegetables (cabbage). On several occasions she noted either bile or blood in her vomitus.
These episodes, according to the patient, were not unlike her prior "attacks" which led to
the removal of her gall bladder in 1950. In the latter part of 1956, she noted the development
of weakness, tiredness and depression. Excepting for the past history of surgical interven.
tion, appendectomy (1925), hysterectomy and salpingectomy (1954), the history was
non-contributory.
Physical examination revealed an obese, short female in no acute or chronic distress. The
pertinent findings were limited almost exclusively to the cutaneous and osseous systems.
The skin of the face, neck and upper extremities was firm, bound-down and shiny. The
fingers appeared to be edematous, cyanotic and cool to touch. The hands were fixed in a
slight position of flexion deformity. Movements of the fingers, wrists, elbows and shoulders
were accompanied by pain. Limitation of motion of the shoulders in all ranges was noted.
The remainder of the physical examination was non-contributory.
Laboratory Data: Hemoglobin 14.6 gm. and white blood count 5,300 with a normal
differential. The serologic findings were negative. Urinalysis was negative for glucose,
albumin and casts. Fasting blood sugar 112 mg. %.Nonprotein nitrogen was reported as 37
mg. %. Thebleeding time, coagulation time and platelets were normal. Total serum protein
was 7.9 gm. with an albumin of 4.3 gm. and globulin of 3.6 gm. Hanger's test was 1+.
Thymol turbidity was recorded as being 2.9 units. Total serum bilirubin 0.3 mg. with a
direct fraction of 0.5 mg. The prothrombin time was 100%. C-reactive protein was 1+.
Serum sodium, chlorides and potassium were 141, 109 and 4.6 meq./L. respectively. Serum
calcium was 10.4 mg. % and phosphorus 4.3 mg. %. 24 hour urinary excretion of copper and
zinc was 0.13 mg./L. and 0.37 mg./L. respectively. Smears for L.E. cells were negative. Free
boundary electrophoresis revealed a slight depression in the albumin fraction. The ECG was
interpreted as being normal. X-ray of the chest revealed cardiac enlargement. Repeated
gastrointestinal roentgenograms revealed no intrinsic disease. X-ray of the teeth demon-
strated no peridontal membrane changes. X-rays of the shoulder and arms were negative.
Those of the hands revealed osteoporosis of the phalanges. Biopsy study of the skin was held
to be suggestive of scleroderma. Von Kossa's stain for calcium was negative.
Therapy consisted of 3 gm. of Na2-EDTA given intravenously daily over a 4 hour period
for five days. Three consecutive courses of such therapy constituted the treatment program.
Clinical changes became apparent during the second week of therapy and consisted of de-
decreased induration and hardness of the facial and upper extremity skin. The greatest
benefit seemed to accrue in the osseous system with remarkable changes in the pain-free
range of motion of the shoulders. These changes were not unlike those induced by steroids in
rheumatoid arthritis minus only the euphoric changes. Biopsy study of the shin of the hand
after therapy revealed no remarkable alteration. Urinary copper and zinc excretion in-
creased to 0.29 mg./L. and 6.99 mg./L. respectively. The patient was discharged November
19, 1956, as improved. She was sent home with instructions to take Na2-EDTA in a dosage of
1 gm. daily. On this dosage schedule there was noted a recurrence of the "arthritic" symp-
toms with the skin showing a slight change in induration.
She was readmitted to the hospital January 6, 1957, for re-evaluation and biochemical
study. She was placed upon a second course of intravenous therapy (3 weeks, 45 gm.). Her
clinical course was again one of definite improvement with a decrease in skin induration and
ircreased joint mobility with very little pain. Calibrated range of motion studies revealed
definite functional improvement. Oscillometrie testing of the lower extremities after ther-
apy indicated definite improvement from a pre-treatment level of 1 to a post-treatment level
of 4 bilaterally. A definite improvement in shin temperature changes of the toes was noted.
The histamine wheal test showed no remarkable changes. The patient was discharged from
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the hospital February 8, 1957 as improved. She was placed on high pharmacological doses of
pyridoxine and nicotinamide on the basis of biochemical changes occurring during the course
of study.
Case III, female, 58 years of age, hospital number 312597, was admitted to the University
Hospitals January 6, 1957, for evaluation and treatment of "scieroderma". According to the
patient, the latter state had been present for 8 years and consisted of swelling and pain in
the hands increased by exposure to cold, "arthritis", stiffness and tightness of the shin of
the face, neck, upper extremities with recurrent ulcerations of the fingertips and ankles. The
initial symptoms appeared in October, 1948, with swelling, pain and immobility of the
fingers of both hands. She was seen by her physician at that time, and the diagnosis of
"arthritis" was entertained and a course of gold injections was given without benefit.
Early in 1949 she noted the appearance of tightness and shiny skin involving the arms
bilaterally. At that time, on the basis of the changes present, together with a skin biopsy, a
diagnosis of scieroderma was made and several courses of PABA were instituted. The
clinical picture was not remarkably altered by this drug. In November, 1953, because of the
increasing pain and stiffness of the hands, the patient was advised to move to a warmer
climate (Arizona). Her sojourn in this area led to a remarkable reduction in her hand pain
and stiffness. Shortly thereafter she returned to her home state with a prompt exacerbation
of her symptoms. She was then placed on hydrocortisone without perceptible relief of her
discomfort. In September, 1954, she noted the onset of small, painful ulcers in her fingertips
and around her ankles, which have persisted to the present time. During this phase of her
disease she was placed on dibenzyline, benadryl, ACTH, thyroid and salicylates without
remarkable change in her clinical condition. In January, 1956, there appeared an inability
to swallow solid foods. There was no history of nausea, vomiting or hematemesis. At this
time a further progression of hand, wrist, shoulder and hip joint pain and stiffness was
described. Because of the limited mobility of her hands, she was no longer able to carry out
the duties of her occupation. Otherwise the history was essentially non-contributory.
Pertinent findings on physical examination consisted of the following. The skin of the
face, neck, arms and hands was shiny, indurated and firmly bound-down. The upper mid-
arms demonstrated a band of atrophy and shininess approximately 3 inches wide. The
fingers of the hands were shortened, deformed, cold and fixed in a position of fiexion. The
palms and fingers were noted to be covered with sweat. Several of the fingertips demon-
strated small areas of ulceration and were painful to touch. A similar process involved the
malleoli of the ankles. While range of motion maneuvers of the wrists, elbows, shoulders,
spine, hips, knees and ankles were not remarkable, pain and discomfort were complained of
by the patient. Other pertinent physical findings consisted of questionable enlargement of
the heart to the left with a grade III harsh systolic murmur present in all the valve areas,
especially the aortic. The blood pressure was normal. The lungs were clear to auscultation
and percussion.
Laboratory Data: Hemoglobin 12.8 gm. and white blood cell count 5,000 with a normal
differential. Urinalysis was negative for glucose, albumin and casts. Serologic findings were
negative. Fasting blood sugar 97 mg. %. Nonprotein nitrogen was 34 mg. %. Hemostatic
tests were negative (bleeding time, coagulation, platelets). Total serum protein was 6.7 gm.
with an albumin of 4.5 and 2.2 gm. Hanger's test was negative. Thymol turbidity was 1.6
units. Prothrombin time was normal (100%). Serum bilirubin was normal. Serum sodium,
chlorides and potassium were 141, 108 and 4.3 meq./L. Serum calcium was 9.2 mg. %and that
of phosphorus 4.5 mg. %. Smears for L.E. cells were negative. Blood uric acid was 4.4 mg. %.
Urinary copper and zinc excretion studies were not done on this patient. Free boundary
electrophoresis revealed a slight lowering of albumin. Biopsy study of the skin of the fore-
arm was compatible with scieroderma. Von Kossa stain for calcium was negative. The ECG
was interpreted as being within normal limits. X-ray of the heart revealed cardiac enlarge-
ment. The lung bases revealed evidence of diffuse fibrosis held to be roentgenologically com-
patible with scleroderma. Gastrointestinal fluoroscopy and x-ray studies were negative for
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intrinsic disease. Roentgenograms of the hands demonstrated absorption of bone in the ter-
minal tufts of the distal phalanges. Small pinpoint foci of calcification was present in the
soft tissues around areas of bone erosion. Marked contraction deformities of the fingers,
especially at the proximal joints, was described. The volume of soft tissue of the fingers was
markedly reduced. X-rays of the forearms and arms were not remarkable. Spine x-rays
revealed a minimal degree of osteoporosis. Range of motion studies of the upper extremities
revealed fiexion-extension aberration exclusively of the hands. Skin temperature determina-
tions of the lower extremities were decreased in the dorsal, plantar toe areas. A less than
normal response in histamine wheal formation was obtained in the lower extremities.
Oscillometric determinations of the lower extremities were essentially within normal limits.
Therapy consisted of 3 gm. of Na2-EDTA given intravenously daily over a 4 hour period
for five days. Three consecutive such courses of therapy constituted the treatment program.
Remarkable clinical changes were noted to appear during the second week of therapy.
Softness and decreased induration of the skin were noted over the face, neck and upper arm
areas. The ability to wrinkle the forehead and to open the mouth were improved when
compared to the pre-treatment findings. The amulet-like areas of scleroderma of the upper
arms were remarkably reduced. Similar, though less dramatic, changes were noted over the
fingers. Subjectively there was noted a definite decrease in pain and stiffness on range of
motion maneuver of the back and upper and lower extremities. Objectively the changes
were slight. The temperature of the fingers and toes appeared to have improved clinically
during the course of therapy; however, objective measuremets utilizing skin temperature,
histamine wheal and oscillometry did not appear to corroborate the subjective observations.
The ulcers present on the fingers and ankles were seen to regress and eventually disappear.
The reduction in pain in these areas was profound. Biopsy study of the skin of the arms
after therapy revealed no remarkable changes. At no time during the therapeutic regimen
was clinical evidence of tetany encountered. The serum calcium levels, determined shortly
after infusion, ranged from 9.2 mg. % to 7.2 mg. %. The clinical evidence of avitaminosis B
as described by Clarke et al. (63) and Perry and Schroeder (65) was not noted in this subject.
DISCUSSION
The clinical response of these three cases of non-calcific (acrosclerotic) sciero-
derma to disodium ethylenediamine tetra-acetic acid has been gratifying and
appears to merit further investigation. When the clinical results are further
evaluated in the frame of the pharmacological aspects of chelation, several obser-
vations are worthy of comment. The experiences reported by Klein and Harris
(43) in their case of scleroderma, scierodactylia, calcinosis and arthritis treated
with the same agent clearly demonstrate the calcium-mobilizing capacity of this
sequestrant in normocalcemic calcinosis. It is of interest to note here that Dil-
laha (90) found no remarkable clinical or laboratory changes in two cases of
diffuse systemic scleroderma treated with Na2-EDTA.
In our subjects a lessened induration and shininess of the skin was definitely
noted clinically. These changes were particularly noticeable in the face, neck and
upper arms. Similar, though less pronounced, changes were noted in the skin of
the hands. The increased mobility of the larger joints (elbow, shoulders, hips,
knees) was likewise striking. It should be noted here that the joint deformities of
the hands appeared to be little influenced by therapy. As far as we have been able
to ascertain, there is no available report in the literature suggesting the possible
efficacy of EDTA in the treatment of the various arthritides. That the drug
should exert any effect in a dynamic way on the vascular system has not been
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reported, according to our investigations. It has been observed that in animals, at
least, the calcium salt lowers skin temperature (86). Whether the sodium salt
exerts any effect on the vasculature is unknown. Nevertheless, the ability of
these subjects to endure a cold (environmental) "challenge" with diminished pain
response is worthy of note. Tests of vascular motion (skin temperature, histamine
wheal and oscifiometry) would indicate that no statistically significant changes
occurred. The healing of the ulcers of the hands and feet was likewise singular in
our cases. The concomitant diminution of pain with healing indicates a further
unexplained effect of this agent.
The possible mechanisms of action of this drug in these cases are several. The
observation of Engel et at (37) that the connective tissues of the body contain
calcium in both the ionic and bound forms in excess of that of blood suggests the
possibility that this compartment might be abnormally laden with an excess of
this divalent cation, eventuating in a state of calcium accumulation without cal-
cilication, as suggested by Armstrong (39). TIns latter observation represents a
new emphasis upon total calcium motion and deposition. While EDTA exerts it
most profound effect upon the richest source of calcium, i.e the appetite lattice
of bone, it may well be that its impact on a smaller compartment (connective
tissue) is even more significant when the latter unit is attacked by a powerful
chelator. Another possible mechanism of action of the sodium salt is equally at-
tractive, namely its possible effects on modifying the little understood magne-
sium-calcium interrelationship. Popovici et at (60) found, as a result of their
animal experiments, that the magnesium ion may have a regulatory action on
calcium metabolism. The simultaneous administration of magnesium ion with a
lethal dose of EDTA resulted in a rapid replenishment of blood calcium levels.
In magnesium excess induced by magnesium salt injection an accompanying fall
of serum calcium to tetanic levels has been noted (87). Tibbetts and Aub (88),
investigating magnesium levels in normal humans, found that magnesium salt
ingestion increased urinary calcium elimination. Menaker and Kleiner (89),
studying the effect of mineral deficiencies in protein synthesis in animals, noted
that deficiency in magnesium exerted an unfavorable effect on protein synthesis.
Little is known about the relationship of the various trace metals to the function
of enzyme systems; however, Gurd and Wilcox (85) suggest several possible ways
in which metal ions may interact in an enzyme system: (a) by chelation with
certain ligand groups, the metal ion may stabilize the active configuration of the
enzyme molecules; (b) by changing the charge on the enzyme molecules, the
binding metal ions may favor the binding of substrates or coenzymes; (c) by
forming a ternary complex with the enzymes and the substrate or coenzyme, the
metal ions may serve to increase the binding of the small molecules at the sites
where it may be activated; and (d) by being bound into the "active center" of
the enzyme the metal ions may be directly involved in the mechanism by which
the substrate or coenzyme is activated. Whether the magnesium ion functions
independently or in harmony with other trace metals in such metal-enzyme
systems as might apply to scleroderma represents a challenging possibility. Thus
it would appear that the use of the magnesium salt of EDTA in scleroderma
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would appear to be clinically justified. Another possibility that cannot be effec-
tively dismissed is that the long time accumulation of such metals as nickel,
aluminum, lead, etc., might in some fashion by their plethora inhibit or block
enzyme actions of important trace metals (magnesium, manganese, cobalt, etc.)
with the resultant immobilization of metal-connective tissue physiology. It
might be further speculated that the effects of this drug is such that properties
not characteristic of the ligand and metal result from the artificially induced
union. Finally, the introduction into the human body of this unnatural polya-
mine, polycarboxylic acid, might result in changes that are in no way related to
its chelating properties. In view of these speculations, it would not appear
inapropos to review what is known about sequestering compounds.
The chemistry and pharmacology of the metal chelate compounds is complex
and in essence represents a new frontier whose borders are far from being precisely
or finally delineated. The reader is referred to the standard studies by Martell
and Calvin (45), Calvin (46) and Wiffiams (47, 48). Nevertheless it would not
seem inapropos to present a synoptic review of the highlights of this branch of
chemistry and pharmacology, emphasizing in particular the identification of
those actions of drugs which appear to be related to chelation. Much of the infor-
mation to be presented here has been secured from a thorough study by Cheno-
weth (49), published in 1956.
Chelate compounds, from the Greek "chele", the crab's claw, have only re-
cently begun to occupy a prominent place in pharmacological and medical lit-
erature. Research attention and speculation have been directed more and more
in the direction of those metals (iron, cobalt, manganese, magnesium, copper
and zinc) which are integrally involved in the normal biochemistry of cellular
systems.
Briefly, according to present day chemical theory, chelate compounds are es-
sentially co-ordinate compounds with the co-ordinate bonds arising from the
sharing of an electron pair between the ion or atom of a metal and an ion or atom
in the complex forming structure (ligand). The most common electron-donating
or electron-sharing atoms in ligand molecules are nitrogen, oxygen and sulfur,
although others are known. When two bonding groups are present with proper
spatial orientation in a single molecule, a heterocyclic ring involving the metal
ion may be formed in contrast to a "complex" which exists in a non-ring form.
One classification of chelate compounds is based upon the number of ligands tied
together in a single or multiple claw, i.e. monodentate, bidentate (a single ring
being formed) etc. Generally, the most stable chelate rings consist of five and six
members and are among those most frequently encountered although others have
been described. The formation of these rings is of utmost biological importance
in that they confer behavior properties upon both the chelated metal and the
ligands not previously characteristic of either alone.
The two most important factors in the formation of a complex are the pH of a
solution and the stability constant. The latter concept must not be accepted
without the appreciated restriction that it may not indicate the biologically most
important metal. Furthermore, in vitro chelation capacities may not represent
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the sole factor in predicting drug chelation activity since the rest of the molecule
may influence such phenomena as penetration, steric hindrance, etc. Drill (83)
raises the possibility that the introduction of EDTA into physiological surround-
ings might result in a pharmacological effect in its own right by virtue of its
unnatural amino acid structure or that its pharmacological action might be due
to its ability to combine with metal ions in vitro. The problem is further compli-
cated by virtue of the large concentrations of metals or ligands which are present
under physiological conditions relative to the metal or metals of interest. In the
exhibition of a variety of ligands there is a tendency for metals to follow an order
of descending stabilities generally the same for each ligand. Irving and Williams
(50) have shown that the relative affinity of bivalent cations of the first transition
series of the periodic table to be as follows: Mn <Co <Ni < Cu <Zn irrespective
of the nature of the co-ordinated ligand or the number of ligands involved. Mellon
and Maley (51, 52), using salicaldehyde complexes, arrived at a series in the
following order of decreasing chelate stability: Pb, Cu, Ni, Co, Zn
Fe, Mn, Mg. It is apparent then that the strength of binding varies
with the cation. The property which is of value to the clinician in chelates with
ethylenediamine tetra-acetic acid is that of releasing a weakly bound cation and
taking in exchange a more strongly bound one.
Experimental and speculative evidence seems to indicate that there are several
mechanisms by which a chelating compound may influence cells: the sequestra-
tion of unwanted metals, the removal of metals from intact organisms, the reaction
with fixed intracellular metals, catalysis, the tissue ligand—extraneous metal
relationship, and the improvement of absorption (soils). Isolated examples of
some of these mechanisms are known to the clinician, viz., BAL (53) wherein
toxic metals are removed from organisms by producing a less toxic chelate and
nickel eczema (54) where a diet rich in citrus fruits leads to the excretion of
chelate complexes. The long-known relationship that mercury and arsenic can
form chelates interfering with the normal function of cellular ligands represents
an example of tissue ligand—extraneous metal union. Another example of this
type of reaction is that of the chelation of zirconium by the toxin of rhus toxi-
codendron and the application of the concept clinically (55, 56).
The singular properties of ethylenediamine tetra-acetic acid and its salts
(monocalcium disodium (Ca Na2-EDTA) and disodium (Na2-EDTA)) have
given clinical investigators a substance which may be used precisely for its
remarkably powerful chelating capacities. This synthetic polyamino polycar-
boxylic acid is usually given intravenously as the calcium disodium salt (Ca
Na-EDTA) when the sequestration of calcium is not the main aim of therapy.
The reduction of blood calcium levels is best accomplished by the use of disodium
ethylenediamine tetra-acetic acid (Na2-EDTA).
EDTA and its salts are virtually non-toxic by any route of exposure. Foreman,
et al (57) performed studies with Ca Na2-EDTA and were able to demonstrate
reversible tubular degeneration in rats after prolonged administration of large
doses (203 mg./Kg per day) of the drug. Using the C' labelled calcium salt in
the rat, Foreman et at (58) found that essentially all of the drug passed
through the body unchanged with 95—98% of the parenterally administered
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compound being excreted in the urine within six hours. Study with human beings
using C'4 labelled material (59) indicated that Ca Na2-EDTA passes through the
body unchanged via the urinary tract within 24 hours. The mode of excretion
was renal involving both the glomerular and the tubular apparatus. The drug
did not pass into the erythrocytes and migrated relatively slowly into the spinal
fluid. Poor gastrointestinal (5%) and cutaneous absorption was noted; however,
Popovici et at (60) observed that the daily application of a water soluble prepara-
tion of EDTA to the skin of human subjects decreased serum calcium to 8 mg. %
after four days. Spencer et at (61) studied the effect of intravenously administered
Na,-EDTA upon calcium blood levels and urinary excretion in normals and in
patients with osteoporosis, osteoplastic metastases and multiple myeloma. They
found that the maintenance of serum calcium levels was due to the replenish-
ment of calcium from the skeletal system. The extent and rate of such demineral-
ization of the skeleton was found to be dependent upon the quantity of the
chelating agent and the speed of its infusion rather than on the state of the
skeletal system; however, the serum calcium levels, determined by direct oxalate
precipitation, showed no significant lowering during or after the infusion of the
sodium salt. Total calcium determined on the acid ashed serum was significantly
higher during the infusion and up to 18 hours after its completion. Cotter (62)
described slight changes in plasma trace metal levels in a lead-poisoned patient
treated with Ca Na,-EDTA noting no adverse effects upon the general clinical
status.
Toxicity and side effects data in human beings treated with EDTA while few
nevertheless point to the possibility that in certain cases the treatment program
may eventuate in serious consequences. Dudley et at (63) employed parenteral
Na2-EDTA in the treatment of a woman dying with osteolytic metastases and in
a child acutely ifi due to hypervitaminosis D. They felt that the severe damage
due to the renal tubules, the engorgement of reticulo-endothelial cells with
coarse eosinophilic granules, and the hemorrhagic manifestation found at autopsy
were related to the drug. Foreman et at (57) noted renal disturbances which were
transitory and disappeared after cessation of therapy in a 40 year old female
treated with Ca Na,-EDTA. Clarke et at (64), using the sodium salt to dissolve
metastatic calcium in a series of patients, described a local burning sensation at
the site of the infusion. Mild nausea and diarrhea were noted in several subjects.
Five cases in this series developed toxic skin and mucous membrane reactions
which subsided rapidly when the medication was discontinued. Toxic reactions
were markedly reduced by the oral administration of pyridoxine (B6). These
same workers in a subsequent publication (65) reported the sudden death of a
patient suffering from angina pectoris who had been treated with Na2-EDTA.
They believed that the clinical evidence suggested death as being due to calcium
embolization. Perry and Schroeder (66) treated a 44 year old white male with
amyloid nephrosis using Ca Na2-EDTA. After 5 days of therapy there appeared
mucous membrane and skin lesions which to them suggested avitaminosis B. The
drug was stopped and the patient was given riboflavin, nicotinamide and pyri-
doxal hydrochloride with recovery.
The interim opinion for a program of treatment with the calcium salt has been
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summarized by Foreman et at (81). This group of investigators suggests that the
maximum dose should not exceed 0.5 gm./30 lb. body weight/hour as an intra-
venous drip of a 3% solution. The maximum dose per day should not exceed
1.0 grn./30 lb. of body weight. The course of therapy should be distributed over a
7 day period with a weeks rest before repetition. The dosage, precautions and
contraindications for the administration of the disodium salt have likewise been
outlined (82). It is recommended that the adult daily dosage should be 50 mg.
per kilogram with a daily maximum for any patient of 5 grams. The drug is
given intravenously dissolved in 500 cc. of 5% glucose in water or in normal
saline. The infusion time should be adjusted to occupy 4 hours. A suggested
"course" consists of infusing the drug for 5 days with a 2 day rest and repeating
this cycle three times. After an interval of several weeks, the "course" may he
repeated should clinical conditions so indicate. Clarke et al (64), in their clinical
experiences with the sodium salt in angina pectoris, commented upon the "con-
tinuing action" of the drug after its use. It has been recommended that
Na2-EDTA not be used in the presence of acute renal disease and that the occur-
rence of any unusual urinary findings during therapy should be an indication for
withdrawal (81). The same report has underscored the need for close observations
as to signs of hypocalcemic tetany; however, in none of the cases reported wherein
the disodium salt was exhibited, has this circumstance occurred. Generally the
close observations of slow intravenous infusion (4 hours) minimized this possi-
bility. In those cases with clinical evidence of atherosclerosis the course of therapy
should be shortened with frequent rest periods.
The clinical efficacy of EDTA in the treatment of various disease states has
been increasingly documented: the clinical dissolution of urinary calculi (67,
68), in the separation, concentration and transfusion of platelets (69), blood
preservation (70), lead poisoning (71), hemochromatosis (72, 73), plutonium
poisoning (74), corneal opacities (75) and lime burns of the eye (76) hypertension
(77, 78), as a means of lowering blood cholesterol (78—80) and in angina pectoris
(64, 65).
It would appear then that clinical medicine has available for its use a drug
whose full potential is yet to be explored. The impact of this potential has been
best expressed by Martin (84) in a review of ion exchange and adsorption agents
in medicine, when he observes: "there will be indications for the use of these
agents in the removal of toxic cations and doubtless indications for the use of
such chemicals for gaining transfer of cations into cells. Sequestrants will serve
as mechanisms of transportation for otherwise difficult transferrable units from
one side to another. Chelation is doubtless the key to those chemical forces which
cause the bending, twisting and turning of protein molecules creating, as a result,
complex molecules endowed with the characteristics of life. Ion antagonism as a
subdivision of the general field of biological antagonisms will be involved. There
is no more basic approach to the general field of medical practice."
CONCLUSIONS
1. Three cases of non-calcific scieroderma (acroscierosis) have been treated
with a chelating agent, disodium ethylenediamine tetra-acetic acid, (Endrate).
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The clinical effects of this agent have been documented. The diminished indura-
tion of the skin, the reduction in joint pain, the apparent increased rate of ulcer
healing appear to be impressive. The paucity of drug side effects have likewise
been noted.
2. The chemistry and pharmacology of chelation has been reviewed and
pertinent observations applied to scieroderma. The possible significance of
metal-binding systems in cutaneous medicine has been implied.
3. The concept that chronic and morbid disease processes might be related at
least in part to metal-binding anomalies suggests a new therapeutic approach
in clinical medicine.
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